{"component": "definition", "props": {"groups": [{"samples": [{"hash": "klsoJvkwYek", "uri": "/contracts/klsoJvkwYek#bms-agreement", "label": "License and Collaboration Agreement (Genmab a/S)", "score": 30.4017791748, "published": true}, {"hash": "9IyrDdoXRnW", "uri": "/contracts/9IyrDdoXRnW#bms-agreement", "label": "License and Collaboration Agreement (Genmab a/S)", "score": 30.2484607697, "published": true}], "snippet_links": [{"key": "agreement-between", "type": "clause", "offset": [18, 35]}, {"key": "as-amended", "type": "definition", "offset": [61, 71]}], "size": 4, "snippet": "means the License Agreement between BMS and SGI dated [***], as amended.", "hash": "a565b6332db4ddaf004decafc3b26b67", "id": 1}, {"samples": [{"hash": "lmD2JaCI1dd", "uri": "/contracts/lmD2JaCI1dd#bms-agreement", "label": "Development and License Agreement (Seattle Genetics Inc /Wa)", "score": 21.0, "published": true}, {"hash": "kjKxff9nQr7", "uri": "/contracts/kjKxff9nQr7#bms-agreement", "label": "Development and License Agreement (Seattle Genetics Inc /Wa)", "score": 21.0, "published": true}, {"hash": "aWtYBbIijhA", "uri": "/contracts/aWtYBbIijhA#bms-agreement", "label": "Development and License Agreement (Seattle Genetics Inc /Wa)", "score": 21.0, "published": true}], "snippet_links": [{"key": "agreement-between", "type": "clause", "offset": [18, 35]}, {"key": "dated-as-of", "type": "definition", "offset": [80, 91]}], "size": 3, "snippet": "means the License Agreement between \u2587\u2587\u2587\u2587\u2587\u2587\u2587-\u2587\u2587\u2587\u2587\u2587 Squibb Company (\"BMS\") and SG dated as of March 30, 1998.", "hash": "71cc84bff5a78a6cd186c193ea87917e", "id": 2}, {"samples": [{"hash": "gQDifbg3zlZ", "uri": "/contracts/gQDifbg3zlZ#bms-agreement", "label": "Asset Purchase Agreement (Aegerion Pharmaceuticals, Inc.)", "score": 26.5112934113, "published": true}, {"hash": "l7inrnU1PZe", "uri": "/contracts/l7inrnU1PZe#bms-agreement", "label": "Asset Purchase Agreement (Aegerion Pharmaceuticals, Inc.)", "score": 26.1635856628, "published": true}], "snippet_links": [{"key": "agreement-to-be", "type": "clause", "offset": [10, 25]}, {"key": "entered-into", "type": "clause", "offset": [26, 38]}, {"key": "at-closing", "type": "clause", "offset": [39, 49]}, {"key": "relating-to", "type": "definition", "offset": [50, 61]}, {"key": "seller-and-its-affiliates", "type": "clause", "offset": [85, 110]}, {"key": "the-amended-and-restated", "type": "clause", "offset": [117, 141]}, {"key": "stock-and-asset-purchase-agreement", "type": "definition", "offset": [142, 176]}, {"key": "dated-as-of", "type": "definition", "offset": [178, 189]}, {"key": "affiliates-of-seller", "type": "clause", "offset": [223, 243]}, {"key": "terms-of", "type": "clause", "offset": [261, 269]}], "size": 3, "snippet": "means the agreement to be entered into at Closing relating to certain obligations of Seller and its Affiliates under the Amended and Restated Stock and Asset Purchase Agreement, dated as of January 31, 2014, by and between Affiliates of Seller and BMS, the key terms of which are set forth on Exhibit B.", "hash": "1b878bcf3c14e56c2243ffcdb1320db5", "id": 3}, {"samples": [{"hash": "k0LSclfki7Z", "uri": "/contracts/k0LSclfki7Z#bms-agreement", "label": "Technology Transfer and License Agreement (Ocera Therapeutics, Inc.)", "score": 25.4079399109, "published": true}, {"hash": "2uBt6nt8t1U", "uri": "/contracts/2uBt6nt8t1U#bms-agreement", "label": "Technology Transfer and License Agreement (Ocera Therapeutics, Inc.)", "score": 25.3121147156, "published": true}], "snippet_links": [{"key": "the-definition-of", "type": "definition", "offset": [14, 31]}, {"key": "prior-third-party-agreements", "type": "definition", "offset": [32, 60]}], "size": 2, "snippet": "is defined in the definition of Prior Third Party Agreements.", "hash": "596b88908d80560872d799cb3188a877", "id": 4}, {"samples": [{"hash": "jaOnyUnXasm", "uri": "/contracts/jaOnyUnXasm#bms-agreement", "label": "Purchase and Sale Agreement (Agenus Inc)", "score": 35.6009597778, "published": true}, {"hash": "j6tyxwAQ8ZP", "uri": "/contracts/j6tyxwAQ8ZP#bms-agreement", "label": "Purchase and Sale Agreement (Ligand Pharmaceuticals Inc)", "score": 35.5982208252, "published": true}], "snippet_links": [{"key": "commercialization-agreement", "type": "definition", "offset": [44, 71]}, {"key": "dated-as-of", "type": "definition", "offset": [73, 84]}, {"key": "the-company", "type": "definition", "offset": [114, 125]}, {"key": "as-amended", "type": "definition", "offset": [135, 145]}, {"key": "from-time-to-time", "type": "clause", "offset": [146, 163]}, {"key": "terms-of-this-agreement", "type": "clause", "offset": [184, 207]}, {"key": "with-respect-to", "type": "clause", "offset": [208, 223]}, {"key": "the-amendment", "type": "clause", "offset": [224, 237]}], "size": 2, "snippet": "means that certain License, Development and Commercialization Agreement, dated as of May 17, 2021, by and between the Company and BMS, as amended from time to time (but subject to the terms of this Agreement with respect to the amendment thereof).", "hash": "ac8a21121c4a1f5c990cff6c33b3efa1", "id": 5}, {"samples": [{"hash": "2hRFsFyr0ao", "uri": "/contracts/2hRFsFyr0ao#bms-agreement", "label": "License Agreement (Atrium Therapeutics, Inc.)", "score": 37.1560574949, "published": true}, {"hash": "k1hLeBEG9xm", "uri": "/contracts/k1hLeBEG9xm#bms-agreement", "label": "License Agreement (Atrium Therapeutics, Inc.)", "score": 37.0793991089, "published": true}], "snippet_links": [{"key": "research-collaboration-and-license-agreement", "type": "clause", "offset": [19, 63]}, {"key": "entered-into", "type": "clause", "offset": [64, 76]}, {"key": "company-and-\u2587", "type": "clause", "offset": [96, 109]}, {"key": "but-excluding", "type": "clause", "offset": [171, 184]}, {"key": "subsequent-amendments", "type": "clause", "offset": [189, 210]}], "size": 2, "snippet": "means that certain Research Collaboration and License Agreement entered into by and between the Company and \u2587\u2587\u2587\u2587\u2587\u2587\u2587-\u2587\u2587\u2587\u2587\u2587 Squibb Company (\u201cBMS\u201d), dated November 27, 2023, but excluding any subsequent amendments, modifications or restatements thereof.", "hash": "c3293cd5d95b2dce92a1c36e63079be7", "id": 6}, {"samples": [{"hash": "ii2E6pPqyM2", "uri": "/contracts/ii2E6pPqyM2#bms-agreement", "label": "Collaboration Agreement (Seattle Genetics Inc /Wa)", "score": 21.0, "published": true}, {"hash": "fmgRkxXTGq9", "uri": "/contracts/fmgRkxXTGq9#bms-agreement", "label": "Collaboration Agreement (Seattle Genetics Inc /Wa)", "score": 21.0, "published": true}], "snippet_links": [{"key": "agreement-between", "type": "clause", "offset": [18, 35]}, {"key": "as-amended", "type": "definition", "offset": [95, 105]}], "size": 2, "snippet": "means the License Agreement between SGI and \u2587\u2587\u2587\u2587\u2587\u2587\u2587-\u2587\u2587\u2587\u2587\u2587 Squibb Company dated March 30, 1998, as amended on June 8, 1998, June 26, 1998, July 29, 1999, July 26, 2000 and March 22, 2002.", "hash": "a715d93fd548c0ea49d197f9ac726f6f", "id": 7}, {"samples": [{"hash": "cPuMWVeFaZP", "uri": "/contracts/cPuMWVeFaZP#bms-agreement", "label": "Asset Purchase Agreement (Napro Biotherapeutics Inc)", "score": 21.0, "published": true}], "snippet_links": [{"key": "license-agreement", "type": "definition", "offset": [22, 39]}], "size": 1, "snippet": "means the Release and License Agreement, dated November 28, 2001, by and among \u2587\u2587\u2587\u2587\u2587\u2587\u2587-\u2587\u2587\u2587\u2587\u2587 Squibb Company, Seller and \u2587\u2587\u2587\u2587\u2587\u2587 Laboratories.", "hash": "2b88a248aafefe81e5d94e277e8ad854", "id": 8}, {"samples": [{"hash": "c5weWmpLe2W", "uri": "/contracts/c5weWmpLe2W#bms-agreement", "label": "Financing Agreement (Clovis Oncology, Inc.)", "score": 30.3305950165, "published": true}], "snippet_links": [{"key": "clinical-trial", "type": "definition", "offset": [17, 31]}, {"key": "collaboration-agreement", "type": "clause", "offset": [32, 55]}, {"key": "and-company", "type": "clause", "offset": [100, 111]}, {"key": "as-amended", "type": "definition", "offset": [134, 144]}, {"key": "from-time-to-time", "type": "clause", "offset": [214, 231]}, {"key": "in-accordance-with", "type": "definition", "offset": [232, 250]}, {"key": "this-agreement", "type": "clause", "offset": [251, 265]}], "size": 1, "snippet": "means the Master Clinical Trial Collaboration Agreement by and between \u2587\u2587\u2587\u2587\u2587\u2587\u2587-\u2587\u2587\u2587\u2587\u2587 Squibb Company and Company, dated July 31, 2017, as amended August 23, 2018 and February 25, 2019, and as may be further amended from time to time in accordance with this Agreement.", "hash": "c0ab650d60f7212aa6efb1e001d3edf9", "id": 9}, {"samples": [{"hash": "9xEZZwDTjzt", "uri": "https://www.sec.gov/Archives/edgar/data/1338042/000119312507123502/dex31.htm", "label": "Certificate of Incorporation (Aegerion Pharmaceuticals, Inc.)", "score": 9.0, "published": false}], "snippet_links": [{"key": "definitive-agreement", "type": "clause", "offset": [8, 28]}, {"key": "university-of-pennsylvania", "type": "clause", "offset": [58, 84]}, {"key": "form-and-substance", "type": "clause", "offset": [140, 158]}, {"key": "series-a-majority", "type": "definition", "offset": [188, 205]}, {"key": "sole-discretion", "type": "clause", "offset": [215, 230]}, {"key": "entered-into", "type": "clause", "offset": [232, 244]}, {"key": "pursuant-to", "type": "clause", "offset": [245, 256]}, {"key": "consistent-with", "type": "definition", "offset": [261, 276]}, {"key": "letter-of-intent", "type": "definition", "offset": [290, 306]}, {"key": "preferred-stock-purchase-agreement", "type": "clause", "offset": [364, 398]}], "size": 1, "snippet": "means a definitive agreement, between The Trustees of The University of Pennsylvania (\u201cUPenn\u201d) and Bristol-Myers Squibb Company (\u201cBMS\u201d), in form and substance satisfactory to the Required Series A Majority in their sole discretion, entered into pursuant to and consistent with that certain Letter of intent between UPenn and BMS referred to in Section 2.13 of the Preferred Stock Purchase Agreement.", "hash": "be87f8cd9007ecab0e3c45685f0842dc", "id": 10}], "next_curs": "CloSVGoVc35sYXdpbnNpZGVyY29udHJhY3RzcjYLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIWYm1zLWFncmVlbWVudCMwMDAwMDAwYQyiAQJlbhgAIAA=", "definition": {"title": "BMS Agreement", "size": 28, "snippet": "means the License Agreement between BMS and SGI dated [***], as amended.", "id": "bms-agreement", "examples": ["SGI represents and warrants that all royalties owed to BMS pursuant to the <strong>BMS Agreement</strong> are described in this Agreement.", "Genmab shall also require any such Sublicensee to agree in writing to keep books and records and permit either Genmab or SGI or both to audit the information concerning such books and records in accordance with the terms of this Agreement (and in accordance with the terms of the <strong>BMS Agreement</strong> as applicable).", "All rights and obligations under the <strong>BMS Agreement</strong> shall automatically terminate if Licensee fails to maintain the insurance required under Article 18 of this Agreement.", "Solely for the purpose of this Section 6.4.2, the terms \u201cNet Sales\u201d, \u201cLicensed Products\u201d and \u201cRoyalty Term\u201d and any other relevant terms related to calculation of royalties payable to BMS shall have their respective meanings set forth in the <strong>BMS Agreement</strong>.", "SGI covenants that (a) it will use reasonable commercial efforts to maintain all SGI In-Licenses for the duration of this Agreement, (b) it shall not modify Section 13.7 of the <strong>BMS Agreement</strong> without Licensee\u2019s prior written consent and (c) it shall provide Licensee with prompt written notice if it receives or issues any notice of breach or alleged breach under the SGI In-Licenses.", "The Parties agree that BMS is a Third Party beneficiary to this Agreement to the extent SGI Technology includes technology sublicensed under the <strong>BMS Agreement</strong> and limited to those rights and obligations of this Agreement which SGI are obliged to impose on its sublicensees pursuant to the terms of the <strong>BMS Agreement</strong>.", "The Parties agree that BMS is a Third Party beneficiary of this Agreement solely to the extent SGI Technology licensed to Licensee hereunder includes technology sublicensed by SGI under the <strong>BMS Agreement</strong>.", "All rights and obligations under the <strong>BMS Agreement</strong> shall automatically terminate if Genmab fails to maintain the insurance required under the <strong>BMS Agreement</strong>.", "With respect to the BMS Technology, GNE hereby agrees to comply with the covenants and conditions of the <strong>BMS Agreement</strong> set forth in Exhibit C hereto as if they were a party to the <strong>BMS Agreement</strong>.", "SGI shall maintain the <strong>BMS Agreement</strong> for the term of this Agreement."], "related": [["nims-agreement", "NIMS Agreement", "NIMS Agreement"], ["sps-agreement", "SPS Agreement", "SPS Agreement"], ["placement-agreement", "Placement Agreement", "Placement Agreement"], ["\u2587\u2587\u2587\u2587\u2587\u2587-agreement", "\u2587\u2587\u2587\u2587\u2587\u2587 Agreement", "\u2587\u2587\u2587\u2587\u2587\u2587 Agreement"], ["trips-agreement", "TRIPS Agreement", "TRIPS Agreement"]], "related_snippets": [], "updated": "2026-03-01T05:21:46+00:00"}, "json": true, "cursor": ""}}